Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the latest deal Novo has struck to expand its obesity pipeline.